Windlas Biotech Ltd

Windlas Biotech experienced a notable rebound on February 20, 2025, gaining 8.99% after five days of decline. The stock outperformed its sector and reached an intraday high of Rs 775, despite ongoing volatility and trading below key moving averages. Over the past month, it has faced a significant decline.

Windlas Biotech's stock has faced notable volatility, declining significantly today while the broader market remains relatively stable. Over the past month, the stock has dropped considerably, marking five consecutive days of losses. It is currently trading below key moving averages, highlighting a persistent downward trend.

Windlas Biotech has recently experienced a change in evaluation, reflecting its financial performance for Q3 FY24-25, with net sales of Rs 195.02 crore and PBDIT of Rs 24.63 crore. The company has shown strong returns over the past year, significantly outperforming the broader market.

Windlas Biotech has faced notable stock volatility, experiencing a decline over two consecutive days and trading below key moving averages. The stock's recent performance contrasts sharply with broader market indices, reflecting a significant drop over the past month, amid a generally negative trend in the Pharmaceuticals & Drugs sector.

Windlas Biotech announced its financial results for the quarter ending December 2024, reporting record net sales and operating profit. However, the company faces challenges with a declining debtors turnover ratio, indicating potential liquidity and operational efficiency concerns. Stakeholders will be closely watching these evolving trends.

Windlas Biotech has seen a notable decline in its stock performance, dropping significantly today and experiencing consecutive losses over the past three days. The stock's current position relative to various moving averages indicates a mixed short-term trend, while its performance contrasts with the broader market indices.

Windlas Biotech has seen a notable decline in its stock performance, dropping significantly today and experiencing consecutive losses over the past three days. The stock's current position relative to various moving averages indicates a mixed short-term trend, while its performance contrasts with the broader market indices.

Windlas Biotech has seen a notable decline in its stock performance, dropping significantly today and experiencing consecutive losses over the past three days. The stock's current position relative to various moving averages indicates a mixed short-term trend, while its performance contrasts with the broader market indices.

Windlas Biotech has experienced notable trading activity, achieving a significant gain on January 29, 2025, and outperforming its sector. The stock reached an intraday high, reflecting mixed short-term trends in relation to its moving averages. Despite recent gains, it has faced challenges over the past month.

Windlas Biotech's stock has declined significantly, dropping 7.17% today and totaling a 10.14% loss over the past two days. The company's performance contrasts with the broader sector's decrease. Additionally, Windlas Biotech's one-month performance shows a decline of 12.98%, amid ongoing market volatility.

Windlas Biotech has encountered significant challenges, experiencing a notable decline in its stock price. The company has underperformed relative to its sector and has seen a substantial drop over the past few days. The broader pharmaceuticals sector is also facing pressure, contributing to the company's struggles.

Windlas Biotech, a smallcap pharmaceutical company, has gained 7.71% in stock performance on November 29, 2024, currently trading at Rs 1128.25. According to MarketsMOJO, the stock has been given a 'Hold' call and has shown high volatility with an intraday high of Rs 1128.25. It has also outperformed the Sensex in the last 2 days and last month, indicating a positive trend.

On November 25th, 2024, Windlas Biotech, a smallcap pharmaceutical company, saw a significant increase in its stock price, gaining 8.7% and currently trading at Rs 1053. The stock has outperformed the sector by 7.79% and has been on a consecutive gain for the last 2 days, rising by 12.87%. It is currently trading above its moving averages, indicating a positive trend. In comparison to the Sensex, Windlas Biotech has performed exceptionally well with a 1-day performance of 15.51% and a 16.31% return in the last month.

Windlas Biotech, a smallcap pharmaceutical company, has reported a stable financial position in the second quarter of fiscal year 2024-2025. The company's operating cash flow and net sales have shown consistent growth, while its PAT has increased by 22.88% year on year. However, the debtors turnover ratio and non-operating income need improvement. MarketsMOJO has recommended a 'Hold' call for the company's stock.

Windlas Biotech, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 1197 on November 6, 2024. The stock has gained 9.71% in the last two days and is outperforming the sector by 7.48%. Its moving averages and 1-year performance also indicate a positive trend.

Windlas Biotech, a smallcap pharmaceutical company, has seen a 12.06% increase in its stock price on November 6, 2024. This is due to the company's strong performance in the market, with its stock reaching a new 52-week and all-time high of Rs. 1197. Windlas Biotech has also outperformed its sector and the Sensex, showcasing its potential for growth in the pharmaceutical industry.

Windlas Biotech, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on November 6, 2024. With a 'Hold' call from MarketsMOJO, the stock has outperformed the sector by 6.07% and has been on a consecutive gain streak for the past 2 days. It also shows a bullish trend, trading higher than its moving averages and outperforming the Sensex by a remarkable 213.99% in the past year.